| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1919 | 2014 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1695 | 2015 |
| iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL M Hallek, BD Cheson, D Catovsky, F Caligaris-Cappio, G Dighiero, ... Blood, The Journal of the American Society of Hematology 131 (25), 2745-2760, 2018 | 1592 | 2018 |
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study P Moreau, H Pylypenko, S Grosicki, I Karamanesht, X Leleu, ... The lancet oncology 12 (5), 431-440, 2011 | 1173 | 2011 |
| Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia JF Seymour, TJ Kipps, B Eichhorst, P Hillmen, J D’Rozario, S Assouline, ... New England Journal of Medicine 378 (12), 1107-1120, 2018 | 939 | 2018 |
| Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up B Eichhorst, T Robak, E Montserrat, P Ghia, CU Niemann, AP Kater, ... Annals of Oncology 32 (1), 23-33, 2021 | 890 | 2021 |
| Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) HM Kantarjian, NP Shah, JE Cortes, M Baccarani, MB Agarwal, ... Blood, The Journal of the American Society of Hematology 119 (5), 1123-1129, 2012 | 787 | 2012 |
| Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia WG Wierda, TJ Kipps, J Mayer, S Stilgenbauer, CD Williams, A Hellmann, ... Journal of Clinical Oncology 28 (10), 1749, 2010 | 786 | 2010 |
| Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy … RZ Orlowski, A Nagler, P Sonneveld, J Bladé, R Hajek, A Spencer, ... Journal of Clinical Oncology 25 (25), 3892-3901, 2007 | 776 | 2007 |
| Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma SJ Whittaker, MF Demierre, EJ Kim, AH Rook, A Lerner, M Duvic, ... J Clin Oncol 28 (29), 4485-4491, 2010 | 745 | 2010 |
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia P Hillmen, AB Skotnicki, T Robak, B Jaksic, A Dmoszynska, J Wu, ... Journal of Clinical Oncology 25 (35), 5616-5623, 2007 | 736 | 2007 |
| Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic … T Robak, A Dmoszynska, P Solal-Céligny, K Warzocha, J Loscertales, ... Journal of clinical oncology 28 (10), 1756-1765, 2010 | 610 | 2010 |
| Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ... Blood, The Journal of the American Society of Hematology 109 (12), 5143-5150, 2007 | 539 | 2007 |
| Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome JE Cortes, FH Heidel, A Hellmann, W Fiedler, BD Smith, T Robak, ... Leukemia 33 (2), 379-389, 2019 | 496 | 2019 |
| Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study B Coiffier, S Lepretre, LM Pedersen, O Gadeberg, H Fredriksen, ... Blood, The Journal of the American Society of Hematology 111 (3), 1094-1100, 2008 | 494 | 2008 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 475 | 2020 |
| Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma T Robak, H Huang, J Jin, J Zhu, T Liu, O Samoilova, H Pylypenko, ... New England Journal of Medicine 372 (10), 944-953, 2015 | 424 | 2015 |
| Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label … P Hillmen, T Robak, A Janssens, KG Babu, J Kloczko, S Grosicki, ... The Lancet 385 (9980), 1873-1883, 2015 | 418 | 2015 |
| Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial JC Byrd, P Hillmen, P Ghia, AP Kater, A Chanan-Khan, RR Furman, ... Journal of clinical oncology 39 (31), 3441, 2021 | 391 | 2021 |
| Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia RJ Kreitman, MS Tallman, T Robak, S Coutre, WH Wilson, ... Journal of Clinical Oncology 30 (15), 1822, 2012 | 389 | 2012 |
